"There is a huge unmet need for systems to rapidly and accurately diagnose clinical infections and to control nosocomial infections," added Corey Mulloy of Highland. "We believe that OpGen's technology is uniquely placed to meet this need and to transform clinical microbiology."
OpGen is actively expanding both its product development and senior management team. A retained search for a new Chief Executive Officer is currently under way.
OpGen is commercializing a novel single molecule DNA analysis technology, "Optical Mapping", for rapid identification and analysis of microorganisms. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning, or probes. Applications of the new commercial systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products. For more information, please visit http://www.opgen.com or call 603-441-8100.
About CHL Medical Partners
CHL Medical Partners (http://www.chlmedical.com) is a venture capital firm founded in 1990, managing funds with combined committed capital of more than $300 million. The company invests mainly in start-up and early stage companies in the medical sector. The principals of CHL have been associated with numerous successful companies including GeneOhm Sciences, Incyte Pharmaceuticals, Alexion, Celgene, Amicus Therapeutics, Sempercare, American Renal Associates, Genomic Health, Odyssey Healthcare and Ameripath.
About Highland Capital Partners
Highland Capital Partners was founded with the mission of helping great
people build great companies. Since its inception in 1988, the firm has
taken a sector-focused approach to investing in exceptional healthcare,
information technology, communications and consumer com
|SOURCE OpGen, Inc.|
Copyright©2007 PR Newswire.
All rights reserved